Evidence map›Paper›PMID 27022965›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer.

Charles Cleeland, Roger von Moos, Mark S Walker, Yuanyuan Wang, Jianqing Gao, Mariana Chavez-MacGregor, Alexander Liede, Jorge Arellano, Arun Balakumaran, Yi Qian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charles CleelandDepartment of Symptom Research, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit Number: 1450, Room Number: FCT11.5064, Houston, TX, 77030, USA. ccleeland@mdanderson.org.
Roger von MoosKantonsspital Graubünden, Chur, Switzerland.
Mark S WalkerVector Oncology, Memphis, TN, USA.
Yuanyuan WangIMS Health, Plymouth Meeting, PA, USA.
Jianqing GaoIMS Health, Plymouth Meeting, PA, USA.
Mariana Chavez-MacGregorDepartment of Symptom Research, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit Number: 1450, Room Number: FCT11.5064, Houston, TX, 77030, USA.
Alexander LiedeAmgen Inc., South San Francisco, CA, USA.
Jorge ArellanoAmgen Inc., Thousand Oaks, CA, USA.
Arun BalakumaranAmgen Inc., Thousand Oaks, CA, USA.
Yi QianAmgen Inc., Thousand Oaks, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWomen with breast cancer frequently develop painful bone metastases. This retrospective study was designed to longitudinally characterize patterns of patient-reported symptoms among patients with breast cancer relative to the diagnosis of bone metastases.

methodsPatient records were identified from the Oncology Services Comprehensive Electronic Records (OSCER) database which includes outpatient oncology practices across the USA. Symptom burden was assessed by Patient Care Monitor (PCM) assessments, which are administered as part of routine care in a subset of these practices. Eligible patients were women diagnosed with breast cancer (ICD-9-CM 174.xx) who developed bone metastases (ICD-9-CM 198.5) and had ≥1 PCM assessment between January 2007 and December 2012. The pre-specified endpoint was the occurrence of moderate to severe symptom burden, defined as PCM score ≥4 (0-10 scale).

resultsOne thousand one hundred five women (median age, 61) met the eligibility criteria. Worsening of symptoms, particularly fatigue and pain, occurred in the months leading up to the diagnosis of bone metastases. After bone metastases diagnosis, the rate of increase in the proportion of patients experiencing moderate/severe symptoms slowed, but continued to climb during follow-up. Median time to moderate/severe symptoms was 0.9 month for fatigue, 1 month for pain, 2.9 months for trouble sleeping, and 7.7 months for numbness/tingling. Half of the patients received bone-targeted agents after diagnosis of bone metastases.

conclusionsSymptom burden, especially pain and fatigue, increased both before and after the diagnosis of bone metastases, highlighting the need for proactive monitoring and management of symptoms in breast cancer patients.

Indexed as

Patient Reported Outcome MeasuresAgedBone NeoplasmsBreast NeoplasmsFemaleHumansMiddle AgedRetrospective StudiesBone metastasesBone-targeting agentsMetastatic breast cancerPainSymptom burden

Identifiers

PMID27022965
PMCPMC4917575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.